摘要
目的系统评价中国人群ORMDL鞘脂生物合成调节剂3(ORMDL3)基因rs7216389多态性与哮喘易感性的相关性。方法计算机检索中国生物医学文献数据库、中国知网、维普网、万方、PubMed、Web of Science、Embase数据中关于ORMDL3基因rs7216389多态性与中国人哮喘相关性的病例-对照研究,检索时限从建库至2021年5月。对符合纳入标准的独立研究进行质量评价和资料提取后,采用Stata MP 14软件进行荟萃分析(meta)、敏感性分析和发表偏倚评估,用风险值(OR)和95%置信区间(CI)表示哮喘易感风险。结果根据纳入排除标准,共纳入20项病例-对照研究,合计4368例哮喘患者和4104例对照。Meta分析结果显示,在多种遗传模型中,ORMDL3基因rs7216389多态性与中国人哮喘易感性的相关性均有统计学意义。隐性模型(TT vs.CT+CC)中,OR=1.58,95%CI=1.44~1.72,P<0.01;显性模型(TT+TC vs.CC)中,OR=1.63,95%CI=1.40~1.91,P<0.01;TT vs.CC模型中,OR=1.94,95%CI=1.65~2.28,P<0.01;CT vs.CC模型中,OR=1.29,95%CI=1.10~1.53,P<0.01。结论ORMDL3基因rs7216389 C>T突变是中国人群哮喘易感的高危风险因素。
Objective To systematically evaluate the correlation between rs7216389 polymorphism of ORMDL sphingolipid biosynthesis regulator 3(ORMDL3)gene and asthma susceptibility in Chinese population.Methods Databases including CBM,CNKI,CQVIP,WANFANG,PubMed,Web of Science,Embase databases were used to collect case-control studies prior to May 2021 for ORMDL3 rs7216389 polymorphism that contributed to asthma in Chinese.The independent studies that met the inclusion and exclusion criteria was prepared for quality evaluation and data extraction.Meta-analysis,sensitivity and publication bias test were performed by Stata MP 14 software.The odds ratio(OR)and 95%confidence interval(CI)were used to express the risk of asthma.Results According to the inclusion and exclusion criteria,20 case-control studies were included which containing 4368 cases and 4104 controls.It showed that the correlation between ORMDL3 gene rs7216389 polymorphism and asthma susceptibility in Chinese was statistically significant in a variety of genetic models,including recessive model(OR=1.58,95%CI=1.44-1.72,P<0.01),dominant model(OR=1.63,95%CI=1.40-1.91,P<0.01),TT vs.CC model(OR=1.94,95%CI=1.65-2.28,P<0.01),CT vs.CC model(OR=1.29,95%CI=1.10-1.53,P<0.01).Conclusion The C>T mutation of ORMDL3 rs7216389 is a high risk factor for asthma in Chinese population.
作者
张煜婷
孙蕊娟
谢怡
聂苏秦
ZHANG Yuting;SUN Ruijuan;XIE Yi;NIE Suqin(Molecular Genetics Lab,Shaanxi Jiuzhou Medical Laboratory Co.Ltd.,Shaanxi Province,Xi'an710065,China;Board of Directors,Shaanxi Jiuzhou Biomedical Technology Group,Shaanxi Province,Xi'an710065,China)
出处
《中国当代医药》
CAS
2023年第7期23-28,共6页
China Modern Medicine
